Market openNon-fractional

Arcus Biosciences/RCUS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Arcus Biosciences

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Ticker

RCUS

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology

Headquarters

Hayward, United States

Employees

577

RCUS Metrics

BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$2.99
EPS
0.89
Beta
-
Dividend rate
$1.3B
0.89
5.216
5.074
2.829
4.385
-125.00%
-12.27%
-35.35%
4.72
1.86
1.86
-4.76
99.16%
-22.40%
40.62%
2.55%

What the Analysts think about RCUS

Analyst Ratings

Majority rating from 12 analysts.
Buy

RCUS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2.75% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$145M
367.74%
Net income
-$4M
-95.06%
Profit margin
-2.75%
-98.95%

RCUS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 94.74%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.04
-$0.94
-$1.08
-$0.05
-
Expected
-$1.10
-$1.13
-$1.02
-$0.95
-$1.13
Surprise
-5.33%
-16.72%
5.46%
-94.74%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Arcus Biosciences stock?

Arcus Biosciences (RCUS) has a market cap of $1.3B as of July 23, 2024.

What is the P/E ratio for Arcus Biosciences stock?

The price to earnings (P/E) ratio for Arcus Biosciences (RCUS) stock is 0 as of July 23, 2024.

Does Arcus Biosciences stock pay dividends?

No, Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Arcus Biosciences dividend payment date?

Arcus Biosciences (RCUS) stock does not pay dividends to its shareholders.

What is the beta indicator for Arcus Biosciences?

Arcus Biosciences (RCUS) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Arcus Biosciences stock

Buy or sell Arcus Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing